Search Results - "Burkes R"

Overall survival should be the primary endpoint in clinical trials for advanced non-small-cell lung cancer.

Authors: Cheema, P. K. Burkes, R. L.

Source: Current Oncology. Apr2013, Vol. 20 Issue 2, pe150-e160. 11p. 3 Charts.

This result is not displayed to guests.
Login for full access.

Management of diarrhea induced by epidermal growth factor receptor tyrosine kinase inhibitors.

Authors: Hirsh, V. Blais, N. Burkes, R. et al.

Source: Current Oncology. Dec2014, Vol. 21 Issue 6, p329-336. 8p. 3 Charts.

Canadian Expert Group consensus recommendations: KRAS testing in colorectal cancer.

Authors: Aubin, F. Gill, S. Burkes, R. et al.

Source: Current Oncology. Aug2011, Vol. 18 Issue 4, pe180-e184. 5p. 2 Charts.

6095 POSTER Randomized, Open-label, Phase 3 Study of Panitumumab (Pmab) With FOLFOX4 Vs FOLFOX4 Alone as 1st-line Treatment for Metastatic Colorectal Cancer (mCRC) – the Role of Hypomagnesemia (Hypomag) on Efficacy

Authors: Burkes, R. Siena, S. Cassidy, J. et al.

Source: European Journal of Cancer. Sep2011 Supplement 1, Vol. 47, pS420-S420. 1p.

A randomized trial of the electronic Lung Cancer Symptom Scale for quality-of-life assessment in patients with advanced non-small-cell lung cancer.

Authors: Kuo, J. C. Graham, D. M. Salvarrey, A. et al.

Source: Current Oncology. Apr2020, Vol. 27 Issue 2, pe156-e162. 7p.

Canadian perspectives: update on inhibition of ALK-positive tumours in advanced non-small-cell lung cancer.

Authors: Melosky, B. Cheema, P. Agulnik, J. et al.

Source: Current Oncology. Oct2018, Vol. 25 Issue 5, p317-328. 12p. 2 Diagrams, 3 Charts.

Eastern Canadian Colorectal Cancer Consensus Conference 2013: emerging therapies in the treatment of pancreatic, rectal, and colorectal cancers.

Authors: Di Valentin, T. Asmis, T. Asselah, J. et al.

Source: Current Oncology. Feb2016, Vol. 23 Issue 1, p52-55. 4p.

Eastern Canadian Gastrointestinal Cancer Consensus Conference 2014.

Authors: Tsvetkova, E. Sud, S. Aucoin, N. et al.

Source: Current Oncology. Aug2015, Vol. 22 Issue 4, pe305-e315. 11p. 1 Chart.

Eastern Canadian Colorectal Cancer Consensus Conference: application of new modalities of staging and treatment of gastrointestinal cancers.

Authors: Di Valentin, T. Alam, Y. Ali Alsharm, A. et al.

Source: Current Oncology. Jun2012, Vol. 19 Issue 3, p169-174. 6p.

Enhancing treatment decision-making: pilot study of a treatment decision aid in stage IV non-small cell lung cancer.

Authors: Leighl, N. B. Shepherd, F. A. Zawisza, D. et al.

Source: British Journal of Cancer. 6/3/2008, Vol. 98 Issue 11, p1769-1773. 5p. 2 Charts.

50P Is liver transplantation a treatment option for unresectable colorectal liver metastases? Interim analysis of a phase II trial.

Authors: Rajendran, L. Magyar, C.T.J. Li, Z. et al.

Source: Annals of Oncology. 2024 Supplement 1, Vol. 35, pS24-S25. 2p.

Randomized phase II study of modified FOLFOX-6 in combination with ramucirumab or icrucumab as second-line therapy in patients with metastatic colorectal cancer after disease progression on first-line irinotecan-based therapy.

Authors: Moore, M. Gill, S. Asmis, T. et al.

Source: Annals of Oncology. Dec2016, Vol. 27 Issue 12, p2216-2224. 9p. 2 Diagrams, 3 Charts, 1 Graph.

Biomarker testing and time to treatment decision in patients with advanced nonsmall-cell lung cancer.

Authors: Lim, C. Tsao, M. S. Le, L. W. et al.

Source: Annals of Oncology. Jul2015, Vol. 26 Issue 7, p1415-1421. 7p. 1 Diagram, 2 Charts, 1 Graph.

Cognitive function and fatigue after diagnosis of colorectal cancer.

Authors: Vardy, J. Dhillon, H. M. Pond, G. R. et al.

Source: Annals of Oncology. Dec2014, Vol. 25 Issue 12, p2404-2412. 9p. 1 Diagram, 2 Charts, 1 Graph.

Final results from PRIME: randomized phase III study of panitumumab with FOLFOX4 for first-line treatment of metastatic colorectal cancer.

Authors: Douillard, J. Y. Siena, S. Cassidy, J. et al.

Source: Annals of Oncology. Jul2014, Vol. 25 Issue 7, p1346-1355. 10p.

Association of hypomagnesemia with inferior survival in a phase III, randomized study of cetuximab plus best supportive care versus best supportive care alone: NCIC CTG/AGITG CO.17.

Authors: Vickers, M. M. Karapetis, C. S. Tu, D. et al.

Source: Annals of Oncology. Apr2013, Vol. 24 Issue 4, p953-960. 8p.

The toronto management of initially unresectable liver metastases from colorectal cancer in a living donor liver transplant program.

Authors: Rajendran, L. Claasen, M.P.A.W. Ivanics, T. et al.

Source: HPB (1365-182X). 2023 Supplement 1, Vol. 25, pS2-S2. 1p.

O-020 - Copy number variation in longitudinal liver metastases biopsies in colorectal cancer identifies biomarker candidates of resistance to standard chemotherapy.

Authors: Gambaro, K. Marques, M. McNamara, S. et al.

Source: Annals of Oncology. 2019 Supplement, Vol. 30, piv133-iv133. 1p.

6143 POSTER Study 20050203/PRIME – Effect of Post-Progression Anti-Epidermal Growth Factor Receptor (EGFR) Monoclonal Antibody (mAb) Therapy in Patients With Wild-Type (WT) KRas Metastatic Colorectal Cancer (mCRC)

Authors: Siena, S. Douillard, J.Y. Cassidy, J. et al.

Source: European Journal of Cancer. Sep2011 Supplement 1, Vol. 47, pS435-S435. 1p.